{
  "docId": "019de070-c9e1-7644-aac7-afa340d8795d",
  "docSlug": "fc9db8b68eed863ebdeb09cbc0c7e18a",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 86 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 86,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a three-panel structure to compare preclinical rodent models (left/center) with clinical trial data (right).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c9e1-7644-aac7-afa340d8795d/39",
  "deckHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d",
  "deckJsonHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d.json",
  "deckAnchorHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.46,
        "x": 0.04,
        "y": 0.79
      },
      "kind": "callout",
      "text": "Complimentary efficacy and safety profiles with opportunity for AZD9977 + Farxiga FDC in HF patients with CKD",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1e1563e-19e0-48cb-aaac-05f38630137b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.52,
        "y": 0.79
      },
      "kind": "callout",
      "text": "Adding SGLT2 inhibitor to ERA mitigated fluid retention and reduced albuminuria compared to ERA alone",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4cb708c-f31d-4776-86cb-9b8ce877a9a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "chart",
      "text": "SONAR post hoc sub-analysis: DELIGHT trial data",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fead412-a081-4011-8328-2c5c016329c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.22,
        "x": 0.28,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Rodent model: AZD9977 had a predicted reduced hyperkalemia risk",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7f40178-8d80-4f6c-a10d-483b4b10c1ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.25,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Rodent model: AZD9977 improved cardiac function similar to MRAs",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcacc30c-91b0-4166-995d-7afe44a8c693",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.95,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Mineralocorticoid receptor antagonists 2. Fixed dose combination. 3. The Study of Diabetic Nephropathy with Atrasentan (SONAR). 4. Endothelin receptor antagonist.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d303eb77-1ce9-4e0d-8d5a-12a96fa265c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "AZD9977 and zibotentan combos with opportunity to enhance efficacy",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "776b38b4-8868-48d7-8075-7b4ba95c3398",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Farxiga: novel, fixed-dose combinations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acddc799-81f7-4761-94c6-8a3b3a529abc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 41,
      "from": 36,
      "beatId": "420d707b-2958-4b32-ba18-2b50cdf7f871",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slides 36-41 provide an overview of the market opportunity",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}